Back to News
Market Impact: 0.2
IN8bio Consensus Price Target Raised 12% to $7.14
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
IN8bio's average 12-month analyst price target was raised 12.0% to $7.14 per share from $6.38 on September 11, 2026. The upward revision indicates improving aggregate analyst valuation expectations for the biotechnology company, though the article provides no changes to earnings estimates, ratings, or company fundamentals.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
INAB0.35
More News
- Trump teases more inflationary money for voters ahead of midterm elections, now promising $90 payments after touting $500 and $5,000 checks
- Goldman Sachs says buy these stocks now, ahead of their earnings
- AI will create more jobs than it kills, McKinsey says. The catch: 11 million Americans may need new careers
- Gaza voters want jobs and security as Palestinian elections approach
- Spotify billionaire’s body scan startup has come to America
- I’m an obesity expert and can’t wait for the compounding craze to stop